Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)

NCT02268253 is registered in ClinicalTrials.gov with Stemline Therapeutics, Inc. as lead sponsor.

NCT NCT02268253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02268253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Lead sponsor
Stemline Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 10, 2016
Completion date
March 27, 2023
Enrollment
82 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, myelofibrosis